Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 3/20 | 0.38 |
| ▸ | MERTK | Q12866 | 2/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28298241 | 1.00 | ADORA2A (0.44) | ADORA2AADORA1CHRNB4CHRNA3SYK | |
| SCHEMBL15205956 | 1.00 | ADORA2A (0.44) | ADORA2AADORA1CHRNB4CHRNA3SYK | |
| SCHEMBL300898 | 0.81 | KDM4E (0.57) | MAPK1KDM4EHPGD | |
| SCHEMBL301231 | 0.81 | KDM4E (0.57) | MAPK1KDM4EHPGD | |
| SCHEMBL300897 | 0.81 | KDM4E (0.57) | MAPK1KDM4EHPGD | |
| SCHEMBL2324816 | 0.80 | ADORA2A (0.48) | ADORA2AADORA1CHRNB4CHRNA3SYK | |
| SCHEMBL15205874 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1KDM4EHPGDSIGMAR1 | |
| SCHEMBL2322021 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1MERTKKDM4EHPGD | |
| SCHEMBL29828788 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1MERTKKDM4EHPGD | |
| SCHEMBL28298239 | 0.78 | MAPT (0.38) | ADORA2AADORA1CHRNB4CHRNA3PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2022-09-01 | — | — | US | disclosed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | ADORA2A 4525/4885ADORA1 4740/4885CHRNB4 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.